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The value of prophylactic donor lymphocyte infusion (pDLI) is unclear and differs among diseases and
transplantation protocols. Experience with this approach in patients with acute leukemia undergoing
hematopoietic cell transplantation (HCT) with an alemtuzumab-incorporating conditioning protocol is
lacking. We conducted a single-center prospective study to investigate the applicability and efﬁcacy of
prophylactic donor lymphocyte infusion (pDLI) in patients with leukemia undergoing HCT with a low-dose
alemtuzumab-containing conditioning regimen. Inclusion criteria were high-risk acute myelogenous
leukemia, acute lymphoblastic leukemia, or increasing mixed chimerism. All patients included were tapered
off of immunotherapy. Exclusion criteria were a history of grade II or active graft-versus-host disease
(GVHD). Of the 56 consecutive patients who underwent HCT with an alemtuzumab-containing regimen, 15
patients (8 with acute myelogenous leukemia and 7 with acute lymphoblastic leukemia) met the study
inclusion criteria and received prophylactic DLI (total of 45 infusions) from 7 sibling donors and 8 unrelated
donors. The ﬁrst infusion was given at a median of 162 days posttransplantation. The median number of DLIs
was 3, and the median cumulative CD3þ cell dose was 2  106cells/kg. Six of the 8 patients (75%) who
received pDLI while in mixed chimerism converted to stable, complete donor chimerism. Some 47% of DLI
recipients developed GVHD (4 acute GVHD and 3 with chronic GVHD) after a median cumulative dose of 2 
106 CD3þ cells/kg. After a median follow-up of 575 days, 11 (73%) pDLI recipients were alive. All 4 deaths were
due to GVHD-related causes. None of the patients who received pDLIs relapsed. Patients with leukemia who
received low-dose pDLI after conditioning with alemtuzumab are at low risk for relapse; however, this
approach is associated with a relatively high incidence of severe GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION ﬁnding after alemtuzumab-based conditioning, and whether
Allogeneic hematopoietic cell transplantation (HCT) is an
established treatment for high-risk (HR) hematologic
malignancies; however, relapse remains a major cause of
transplantation failure. Patients with acute myelogenous
leukemia (AML) and acute lymphoblastic leukemia (ALL)
who relapse after allogeneic HCT have a very poor progno-
sis [1]. Particularly for ALL, posttransplantation relapses
cannot be rescued with currently available therapies [2].
Thus, strategies to prevent relapse are highly desirable,
especially when some form of T cell depletion is applied.
Based on the observation that administration of donor
lymphocyte infusion (DLI) can induce a signiﬁcant graft-
versus-leukemia (GVL) effect, which is more effective when
the tumor burden is low, investigators have used prophy-
lactic DLI (pDLI) to minimize the risk of relapse [3]. pDLI is
also given to promote complete chimera states. States of
mixed chimerism (MC) can have varying signiﬁcance,
depending on the underlying disease for which HCT was
performed, transplantation protocol, chimerism assessment
method, level of mixed chimerism, and lineage of the cells
assessed in the chimerism assay [4]. Stable MC is a commondgments on page 80.
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12.07.021MC in these protocols can predict relapse in acute leukemia
patients remains controversial [5-7]. Increasing MC in
AML and ALL, evaluated in serial determinations, allows
identiﬁcation of patients at greater risk for subsequent
relapse [8-12].
The value of pDLI is still unclear and may differ among
diseases and transplantation protocols. The impact of pDLI
after alemtuzumab-incorporating HCT conditioning proto-
cols has been evaluated in patients with lymphomas treated
with reduced-intensity conditioning regimens [13-15];
however, experience is lacking in patients with acute
leukemias, especially in the context of myeloablative-
conditioned HCT. In a previous study, we found that low-
dose alemtuzumab effectively prevented severe acute and
chronic GVHD after sibling or matched unrelated donor
allogeneic HCT [16]. To enhance the GVL effect, we amended
that low-dose alemtuzumab study to include pDLI in patients
at high risk for leukemia relapse. Here we report the appli-
cability and efﬁcacy of this approach.MATERIALS AND METHODS
Patients and Study Design
Fifty-six consecutive patients with AML or Philadelphia chromosome
(Ph)-negative ALL who underwent HCT with an alemtuzumab-based
conditioning regimen were registered for the prospective, Institutional
Review Boarde and Ethics Committeeeapproved pDLI study. Patients were
scheduled to receive pDLI if they had HR AML, ALL, or increasing MC.
Increasing MC was deﬁned either as newly developed MC or a >5% increaseTransplantation.
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with the following features: unfavorable karyotype according to the
Southwest Oncology Group/Eastern Cooperative Oncology Group criteria
[17], secondary or biphenotypic AML, induction failure AML, or greater than
ﬁrst complete remission (CR1) at the time of transplantation. Phþ patients
were not offered pDLI, but received imatinib as posttransplantation therapy
instead. Patients were eligible for pDLI if they had no evidence of relapse, no
active infection or other transplantation-related complications requiring
therapy, no history of acute GVHD grade II or greater or active GVHD at the
time of planned DLI, off immunotherapy, and provided written informed
consent. Sibling donors had to consent for leukapheresis without growth
factor mobilization.
To ensure availability of DLIs from unrelated donors, we routinely
isolated and froze small aliquots of DLIs from sufﬁciently large (>5  106
cells/kg) peripheral blood (PB) stem cell (PBSC) grafts. Requests from
unrelated donors for a second apheresis procedure for the purpose of a pDLI
were not done. pDLI administration was planned to commence 2-4 weeks
after cessation of the prophylactic cyclosporine or earlier in case of
increasing MC. Patients were evaluated every 2-3 weeks after each pDLI and
considered for subsequent pDLIs 4-6 weeks later, only if GVHD (any grade)
or other toxicities (grade 2 according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events, version 3.0) had not
presented. Patients were scheduled to receive up to 6 lymphocyte infusions.
According to the study protocol, occurrence of GVHD, toxicity, and treat-
ment-related mortality (TRM) were assessed in real time. The number of
planned infusions was reduced if 3 patients experienced side effects. As
a result of this design, the last 8 patients in our study cohort were scheduled
to receive up to 3 pDLIs. The starting pDLI dose was 0.5  106 cells/kg in the
unrelated donor setting and 0.75  106 cells/kg in the sibling setting,
respectively, with an acceptable deviation of 0.25  106 cells/kg in the
actual number of infused cells. pDLI dosage escalation was allowed up to
1  106 CD3þ cells/kg for unrelated donors and 1.5  106 CD3þ cells/kg for
sibling donors (except in 1 sibling donor recipient, who received a dose of
3  106 CD3þ cells/kg because of increasing MC under pDLI).
Conditioning Regimens, Donors, Grafts, and Chimerism
Patients with AML received standard chemotherapy-based myeloa-
blative conditioning, and those with ALL received TBI-based myeloablative
conditioning. Patients age >55 years and those with severe comorbidities
received a reduced-toxicity myeloablative regimen consisting of ﬂudar-
abine, carmustine, and melphalan or thiotepa [16]. The stem cell source
was granulocyte colony-stimulatingemobilized PBSCs in all but 2 cases.
Donors were HLA-identical siblings or volunteer unrelated donors (VUDs)
with at least 7 of 8 (A, B, C, and DRB1) HLA allele matches. Patients received
alemtuzumab (Mab-Campath; Genzyme, Leiden, the Netherlands) in
a deescalating dosage manner. Criteria used for deescalation of alemtu-
zumab have been described in detail previously [16]. In brief, the ﬁrst
cohort of 10 patients received a total dose of 20 mg of alemtuzumab given
from day -2 to day -1. After real-time evaluation (ie, of engraftment
kinetics, occurrence of acute GVHD, and TRM), the total dose was deesca-
lated to 15 mg in 6 patients and to 10 mg in 36 patients. Four patients who
underwent HCT during the last time frame received 20 mg of alemtuzumab
because of a low risk for relapse. Cyclosporine was given at a dose of
5 mg/kg starting at day -3. In patients without GVHD, cyclosporine was
tapered starting at day þ60 after sibling donor HCT or after HCT performed
for advanced disease (>CR1) and starting at day þ100 in cases of VUD HCT.
Chimerism was assessed via PCR ampliﬁcation of informative micro-
satellite markers and semiquantitative analysis after gel electrophoresis or,
in some cases, after capillary electrophoresis, as described in detail
previously [10]. Chimerism in PB cells was assayed weekly up to day þ100,
at 3-week intervals from day þ100 to day þ180 and at day þ270 and
day þ365, or whenever the patient was seen in the outpatient clinic.
Whenever we found MC in PB, we further evaluated chimerism in Ficoll
gradient-separated mononuclear cells and/or CD3þ subsets after their
isolation using magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Bone marrow (BM) samples were routinely analyzed at
days þ30 and þ100 and whenever indicated.
Deﬁnitions and Statistical Analysis
Data were evaluated as of November 2011. The current analysis includes
some patients who were reported previously [16] and were analyzed here
with respect to pDLI administration and with a longer follow-up. We clas-
siﬁed post-DLI GVHD according to both clinical features and time of onset.
GVHD with acute-like features was graded according to standard criteria
[18], and GVHD with chronic-like features was graded according to severity
using National Institutes of Health consensus criteria [19]. Patients who
developed post-DLI GVHD (any grade) were treated with high-dose steroids
(2 mg/kg daily for 3 days), with the dosage tapered according to response.Patients who did not respond within 5 days received cyclosporine, with the
addition of mycophenolate mofetil for resistant cases. pDLI-related
mortality (ie, TRM) was deﬁned as death after pDLI therapy from causes
other than relapse. GVHD, TRM, and relapse rates were estimated as
cumulative incidence curves (NCSS, Kaysville, UT), with relapse as
a competing risk for TRM, death in remission as a competing risk for relapse,
and death without GVHD a competing risk for GVHD. Estimates of overall
survival (OS) and relapse-free survival (RFS) were obtained by themethod of
Kaplan and Meier where patients were censored at last follow-up if still
alive. Differences between subgroups were compared using the Fisher exact
test for categorical data and the Mann-Whitney U test for continuous data.
Statistical signiﬁcance was based on P < .05. (Graph Pad Prism, CA).
RESULTS
Stratiﬁcation and Patient Characteristics
The study design is summarized in Figure 1. Out of 56
patients who underwent allogeneic HCT with low-dose
alemtuzumab conditioning, 42 HR patients (27 with AML
and 15 with ALL) met the inclusion criteria and were
screened for pDLI. Fifteen patients (36%) received at least 1
pDLI (Figure 1). Twenty patients (48%) were not eligible for
pDLI owing to GVHD in 9 patients, early death in 4 patients,
early relapse in 4 patients, and transplantation complications
requiring treatment (3 patients; 2 with thyroiditis and 1 with
Bell’s palsy neuropathy). Another 7 patients (17%) did not
receive pDLI even though they were considered potential
pDLI recipients. In 4 of these cases, donor lymphocytes were
not available (1 VUD BM transplant, 2 VUD PBSC transplants
but no donor lymphocytes were frozen, 1 sibling donor
refused to donate), and the remaining 3 patients did not
consent to pDLI administration.
Details of the 15 pDLI recipients are given in Table 1. In
total, 45 pDLI administrations were given to these 15 patients
(median age, 29 years; range, 17-65 years). Seven patients
had ALL (47%), 6 had HR AML (40%), and 2 had standard-risk
AML (13%). At the time of pDLI, 8 patients (53%) demon-
strated MC in PB. Eight patients (53%) received lymphocytes
from a VUD, and 7 patients (47%) received lymphocytes from
a sibling donor. The ﬁrst pDLI was given at a median of
162 days (range, 78-426 days) after HCT. Themedian number
of infusions was 3 (range, 1-6), and the median cumulative
dose given was 2  106 CD3þ cells/kg (range, 0.7-7  106).
Recipients of sibling pDLI received a median dose of 2  106
CD3þ cells/kg (range, 1-7  106), whereas recipients of VUD
pDLI received a median dose of 1.6  106 CD3þ cells/kg
(range 0.7-5.4  106) (P ¼ .27).
Toxicity after pDLI
Overall, 7 of the 15 pDLI recipients (47%; 3 sibling donor,
4 VUD) developed GVHD after a median cumulative CD3þ
cell dose of 2  106 cells/kg (range, 0.7-7  106) and at
a median of 75 days (range, 33-343 days) after the ﬁrst pDLI
and 36 days (range, 11-126 days) after the last pDLI, respec-
tively (Figure 2). GVHD developed after a median cumulative
CD3þ dose of 2.5  106 cells/kg (range, 2-7  106) in sibling
pDLI recipients and 1.5106 cells/kg (range, 0.7-4.5106) in
unrelated pDLI recipients (P ¼ .28). Four of 8 (50%) MC pDLI
recipients developed GVHD, whereas 3 of 7 (43%) CC recip-
ients experienced GVHD. In univariate analysis, we could
not ﬁnd a statistically signiﬁcant difference between the
7 subjects who experienced post-DLI GVHD and the non-
GVHD pDLI recipients (Table 2). The number of pDLIs and the
total cell dose given were dependent on GVHD occurrence
and thus could not be included as variables in the analysis.
Of the 7 patients with GVHD, only 1 case was mild and
easily treatable. Four patients (27%) developed acute-like
GVHD at a median time of 51 days (range, 33-75 days) after
Figure 1. Outline of the study design and patient ﬂow. AA, aplastic anemia; CML, chronic myelogenous leukemia; ED/REL, early death or early relapse; NA, not
available; NHL, non-Hodgkin lymphoma; SR, standard risk. *: Numbers in parentheses indicate the number of patients with MC.
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grade I skin GVHD that resolved with steroids, and 3 recipi-
ents (20%; 2 VUD, 1 sibling donor) experienced fatal, steroid-
refractory grade III liver and/or gut acute-like GVHD, even
though the total CD3þ cell dose was <1  106cells/kg in 2 of
them. Chronic-like GVHDwas seen in 3 subjects (20%) at 147-
343 days after the ﬁrst pDLI; 2 VUD recipients developed
moderate skin chronic-like GVHD, which resolved only after
prolonged (>3 months) immunotherapy in both cases, and
patient 7 experienced fatal bronchiolitis obliterans at
183 days after the ﬁrst pDLI. Regarding other toxicities,
patient 6 presented with isolated reversible thrombocyto-
penia after his fourth pDLI administration, and patient 14
developed increased creatine-phosphokinase levels after 2
subsequent pDLI administrations, which ultimately resolved
spontaneously.Chimerism and Outcome
Of the 8 patients who received pDLI while in MC (median
7.5% recipient cells in PB; range, 5%-15%), 6 (75%) converted
to complete chimerism (CC) after a median of 2.5 pDLI
administrations (range, 1-3) and 1.7  106 cumulative CD3þ
cells/kg (range, 0.7-7  106). All remained in stable CC after
a median follow-up of 717 days (range, 232-1445 days) after
the ﬁrst pDLI. The 2 patients who did not convert to CC had
a drop in the number of recipient cells to <5% and remained
in CR nearly 1 year after their ﬁrst pDLI.
At a median follow-up of 575 days (range, 310-1786 days)
after HCT and 367 days (range, 212-1445 days) after the ﬁrst
pDLI, 11 of 15 (73%) pDLI recipients were alive (median
Karnofsky score, 100%; range, 90%-100%), and 4 recipients
died. Death was attributed to post-DLI GVHD causes in
all cases. Thus, DLI-related mortality was 27%, and mortality
in patients who developed post-DLI GVHD was 57%.
The estimated OS and RFS for pDLI recipients was87%þ/ 9% at 1-year and 72%þ/ 12% at 2 years. None of the
patients who received pDLIs relapsed. Of note, of the 7
patients who were considered eligible for pDLI but did not
receive lymphocytes owing to logistical hurdles (5 with AML
and 2 with ALL), 3 (43%) relapsed after a median follow-up of
619 days (range, 143-965 days). Outcomes of eligible pDLI
candidates who received immunotherapy and those who did
not receive immunotherapy are shown in Figure 3. The 2
groups are too small to allow for statistical comparison.DISCUSSION
Given that immunotherapy seems to be more effective
in stages of impending, rather than overt, relapse, perhaps
the most appropriate platform for DLI is in a prophylactic
setting [3]. The ﬁrst report of prophylactic immunotherapy
dates back to 1995 [20]. Evaluation of pDLI in patients with
leukemia in several transplantation settings have demon-
strated the challenges of this approach [21-27]. However,
with the absence of randomized studies, the value of pDLIs in
leukemia remains unclear. Recently, a prospective collabo-
rative mutlicenter study of childhood AML has suggested
that pDLI can be administrated safely on the basis of MC and
may result in improved survival [12]. The beneﬁt of pDLI may
differ based on disease and transplantation-related factors.
To our knowledge, this is the ﬁrst study that prospectively
evaluates the applicability and efﬁcacy of pDLIs in patients
with acute leukemias receiving with a conditioning regimen
incorporating alemtuzumab. Efforts were made to prede-
termine variables to reduce bias. First, patients included
were clearly deﬁned either at transplantation (HR AML, Ph-
ALL) or by using objective markers (ie, MC) after trans-
plantation. Second, to avoid logistical issues in unrelated
HCT, we routinely cryopreserved donor lymphocytes from
the original graft. Third, starting doses and subsequent doses
were given within a narrowly deﬁned range, and the total
Table 1
Characteristics of the pDLI Recipients
Patient Age Disease Stage
at HCT
Conditioning Donor Chimerism
at First
pDLI
First
pDLI,
Day
Number
of pDLIs
Cumulative
CD3þ Cell
Dose
( 106/kg)
Post-pDLI GVHD,
Grade/Organ(s)
Day of
GVHD after
First/Last
pDLI
Days of
Follow-up
Current
Status
1 58 SR AML CR1 RTC VUD MC 426 6 5.4 No d 1786 Alive, CR, CC
2 29 SR AML CR1 HD Sibling MC 158 3 7 Acute, I/skin 59/28 1603 Alive, CR, CC
3 58 HR AML Relapse RTC Sibling MC 78 3 2.5 Acute, III/liver 43/11 310 Dead (GVHD)
4 43 HR AML CR1 HD VUD CC 161 5 4.5 Chronic, moderate/
skin
343/126 1491 Alive, CR, CC
5 20 B-ALL CR1 HD VUD CC 197 2 0.9 Acute, III/liver, gut 33/18 414 Dead (infection)
6 17 B-ALL CR1 HD Sibling CC 162 4 5.5 No d 1219 Alive, CR, CC
7 20 B-ALL CR2 RTC Sibling CC 119 3 2 Chronic, severe/
lung
183/36 486 Dead (GVHD)
8 30 B-ALL CR1 HD Sibling CC 148 2 2 No d 1051 Alive, CR, CC
9 34 HR AML CR1 HD VUD MC 167 1 0.7 No d 1042 Alive, CR, CC
10 28 T-ALL CR1 HD VUD MC 85 1 0.7 Acute, III/gut 75/75 382 Dead (infection)
11 65 HR AML CR1 RTC VUD MC 182 3 2 Chronic, moderate/
skin
147/84 742 Alive, CR, CC
12 49 HR AML CR1 HD VUD MC 218 4 3.2 No d 575 Alive, CR, MC
13 26 HR AML CR1 HD VUD MC 223 3 1.3 No d 531 Alive, CR, MC
14 24 B-ALL CR1 HD Sibling CC 155 3 1.5 No d 435 Alive, CR, CC
15 26 B-ALL CR1 HD Sibling CC 174 2 1 No d 387 Alive, CR, CC
B-ALL indicates B cell acute lymphoblastic leukemia; HD, high dose; RTC, reduced-toxicity conditioning containing ﬂudarabine, thiotepa, and carmustine [16];
SR, standard risk.
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ﬁned after interim evaluation.
DLI confers a risk of GVHD, especially at higher dosages.
Despite the relatively low cumulative doses of lymphocytes
administered in our cohort (median, 2106 CD3þ cells/kg), 7
of the 15 pDLI recipients experienced GVHD. Importantly, in
all but 1 case, GVHD occurring after pDLIs had signiﬁcant
ramiﬁcations, with 3 patients requiring prolonged immune
suppression and 4 patients ultimately dying of GVHD-related
complications. Two patients developed lethal GVHD after
very low CD3þ cell doses (<1 106 cells/kg), which impelled
us to reduce the total number of infusions from the initially
planned 6 total infusions to 3 total infusions in the last 8
patients enrolled in the study. The small number of patients
and the fact that the majority (73%) of pDLI recipients
received a relative narrow dosage range (0.7-2.5  106 CD3þ
cells/kg) precludes any statement regarding the exact dose
that can be given safely. Lutz et al. [27] also reported a high
incidence of GVHD (67%) after pDLI in patients with ALL,
which prompted them to reduce the doses in subsequent
patients by approximately 10-fold (from 107 to 106 cells per
kg). Thus, although DLI doses up to 10  106 CD3þ cells/kgFigure 2. Toxicity in pDLI recipients. Cumulative incidence rates of pDLI-
related GVHD and TRM measured from the time of ﬁrst pDLI.appear to be safe when given in the relapsed setting [28], we
suggest that much smaller doses should be given in the
prophylactic setting. Lutz et al. [27] reported that ALL
patients who received pDLI while in MC had a higher rate of
GVHD than those who received lymphocytes while in CC. In
our series, by administrating one log lower doses, including
both AML and ALL patients and incorporating alemtuzumab-
based T cell depletion in the conditioning, we could not
verify this observation. Furthermore, we could not identify
any other clinical factors predictive of post-DLI GVHD. In our
study, administration of mobilized pDLI resulted in a similar
incidence of GVHD as steady-state pDLI, despite the fact that
the former were derived from unrelated donors and the
latter were derived from related donors. Retrospective
analyses in relapsed patients have suggested a comparable
incidence of GVHD in granulocyte colony-stimulating
factoreprimed or unprimed DLIs and graft-derived DLIs
[29-32]. Identiﬁcation of biological markers that could
predict the outcome of pDLI therapy is warranted [33].
The reported incidence of TRM after prophylactic DLI
ranges between 6% and 52% [21-27]. In the present study, the
cumulative incidence of TRM was 27%. Barrett et al. [21]
reported a signiﬁcant increase in TRM when pDLI was given
early after BM transplantation. Although in our cohort, the
timing of the ﬁrst pDLI varied according to clinical and
chimeric status, it is noteworthy that both patients who
received their ﬁrst pDLI before day þ100 died due to GVHD.
Therefore, we agree with other groups that have suggested
withholding pDLI beyond day þ100 [27]. All cases of TRM
were attributed to GVHD. In all but 1 case (which was lost to
follow-up), our patients were instructed to immediately
report any symptoms and were routinely seen in the
outpatient clinic every 2-3 weeks after each pDLI. Thus,
we do not believe that the high mortality rate of GVHD is
related to a delay in steroid initiation. Given that GVHD
occurred within 11-126 days after the last lymphocyte infu-
sion, our data underscore the need for close and prolonged
monitoring after each pDLI. However, because most patients
begin to return to their pretransplantation lifestyle rhythms
at the time of planned pDLI, both practical and psychosocial
considerations might discourage them from prophylactic
Figure 3. Outcomes of eligible pDLI candidates with pDLI and without pDLI.
(A) Cumulative incidence rates of relapse (REL) (A), relapse-free survival (RFS)
(B), and overall survival (OS) (C).
Table 2
GVHD after pDLI
pDLI Recipients
with GVHD
pDLI Recipients
without GVHD
P value
Patients, n (%) 7 (47) 8 (53)
Age, years, median (range) 29 (20-65) 28 (17-58) .73
Disease, n (%)
AML 4 (57) 4 (50) 1.00
ALL 3 (43) 4 (50)
Conditioning, n (%)
High dose 4 (57) 7 (87) .28
Reduced toxicity 3 (43) 1 (13)
Alemtuzumab dose, n (%)
20 mg 4 (57) 2 (25) .31
10 mg 3 (43) 6 (75)
Donor, n (%)
Sibling 3 (43) 4 (50) 1.00
Unrelated 4 (57) 4 (50)
Sex, n (%)
Male 3 (43) 5 (62) .62
Female 4 (57) 3 (38)
Sex-mismatched HCT, n (%)
Yes 3 (43) 1 (13) .28
No 4 (57) 7 (87)
Day of ﬁrst pDLI, median
(range)
158 (78-197) 170 (148-426) .12
MC at ﬁrst pDLI, n (%)
No 3 (43) 4 (50) 1.00
Yes 4 (57) 4 (50)
% MC at ﬁrst pDLI, median
(range)
PB MC 5 (0-15) 3 (0-15) .85
T cell MC 5 (0-30) 10 (0-30) .67
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Indeed, in the present study, the 3 pDLI candidates who did
not consent to participating in the study reported such
concerns.
Because pDLIs were given while our patients were free of
leukemia and in a nonrandomized manner, drawing conclu-
sions regarding efﬁcacy is difﬁcult. The fact that all patients
with MC improved chimeric status in close relation to pDLI
administration suggests a graft-versus-lymphohemato-
poietic system effect of low-dose pDLI. However, the MC in
our patients was relatively low (5%-15% recipient cells), and
spontaneous conversions of low-percentage chimerism have
been reported [34,35]. Thus, it remains unclear whether the
conversions observedhere can actually be attributed topDLIs.
Furthermore, conversion to complete chimerism is not clear
evidence of GVL activity. None of the pDLI recipients relapsed,
resulting in a 2-year posttransplantation probability for RFS
and OS of 72%. A comparative statistical analysis between
patientswith andwithout pDLI treatedwith theuniform low-
dose alemtuzumab protocol (a total of 56 patients), although
appealing, is not valid, given that selection of the patients for
pDLI is obvious (patients in CR with no GVHD, no early death,
or relapse).
The present study has some signiﬁcant limitations. It was
a single-center study with a relatively small number of
patients. Even though it focused on patients with acute
leukemias receiving a uniform alemtuzumab-based GVHD
prophylaxis protocol, the study population was heteroge-
neous. Despite the study’s prospective nature, it did not
include a control arm. The time of the ﬁrst pDLI adminis-
tration was not ﬁxed, but varied according to patients’ clin-
ical and chimeric status, and donor lymphocytes were
collected using different methods in sibling and unrelated
recipients. Therefore, no concrete conclusions can be made
regarding optimal cell dose, timing, and intervals ofadministration, or use of mobilized graft-derived versus
steady-state DLIs [32].
Despite these limitations, however, the data reported
herein are informative. Our data show that low doses of
donor lymphocytes after alemtuzumab-incorporating
conditioning are feasible and likely maintain signiﬁcant
antileukemic activity, as suggested by the absence of relapse
in the pDLI recipients. Moreover, our data indicate that even
low CD3þ cell doses may induce severe and fatal GVHDwhen
given in a prophylactic setting, emphasizing the need for
more careful selection of patients scheduled to receive pDLIs.
Novel, sensitive methodologies of monitoring minimal
residual leukemiamay improve the selection of patients who
are in real need of prophylactic immunotherapy (eg, WT1
gene expression, disease-speciﬁc mutation monitoring,
multiparameter ﬂow cytometry [36]). Finally, our data indi-
cate that pDLI probably should not be given very early and not
before day þ100 after transplantation. We suggest starting
pDLI at doses 5  105 CD3þ cells/kg and to escalate, if at all,
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should be monitored very closely after administration, and
prompt initiation of full-dose therapeutic immunosuppres-
sion should be started if signs or symptoms of GVHD develop.
In conclusion, our data illustrate that patients with
leukemias who receive low-dose pDLI after conditioning
with alemtuzumab are at low risk for relapse; however, this
approach is associated with a relatively high incidence of
severe GVHD. Further systematic studies are needed to
determine whether the alemtuzumab-based T cell depletion
had an impact on the high alloreactivity of low-dose pDLIs
identiﬁed in the present study. Collaborative multicenter
randomized trials in individual diseases and transplantation
protocols are needed to clarify the value of pDLI. Data such as
ours presented here may aid in the design of such studies.
The use of engineered lymphocytes through insertion of
suicide genes is a highly promising strategy that may
increase the safety of pDLIs [37,38].
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